Avastin ovarian cancer approval a first for Japan
This article was originally published in Scrip
Chugai/Roche's Avastin (bevacizumab) has been approved in Japan for the treatment of ovarian cancer, marking the fifth local indication for the product but the first regulatory clearance for an anticancer in the country to be based on an investigator-initiated trial.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.